# Ysios Capital

> Ysios Capital is a VC fund backing Biotechnology and Health Care. See 81 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Sebastian, Spain
- Total investments: 81
- Last investment: Jun 2026
- Lead investor: 30%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/ysios-capital
- X (Twitter): http://twitter.com/YsiosCapital
- Website: http://www.ysioscapital.com

Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Founded in 2008, Ysios Capital manages c.a. €350 M through three dedicated funds in life sciences and is led by a team ofprofessionals experienced in building biotech companies.

## Contacts

5 contacts available for Ysios Capital. Shizune tracks 9 team members at Ysios Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ysios-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $3.8M–$62M |
| Series B | $20M–$135M |
| Series C | $27M–$80M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 34 | 42% |
| Health Care | 26 | 32% |
| Medical | 19 | 23% |
| Pharmaceutical | 12 | 15% |
| Therapeutics | 10 | 12% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 19 | 23% |
| Series B | 19 | 23% |
| Series C | 13 | 16% |
| Funding Round | 6 | 7% |
| Series D | 5 | 6% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 12 | 15% |
| United States | 8 | 10% |
| Switzerland | 6 | 7% |
| The Netherlands | 5 | 6% |
| France | 3 | 4% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Cristina Garmendia | Founding Partner and Member of the Board | 0 | https://shizune.co/investors/profile/cristina-garmendia |
| Claudia D’Augusta | Venture Partner | 0 | https://shizune.co/investors/profile/claudia-daugusta-2 |
| Guillem Laporta | Partner | 3 | https://shizune.co/investors/profile/guillem-laporta |
| Joel Mairet | Managing Partner and Co - Founder | 19 | https://shizune.co/investors/profile/joel-jean-mairet |
| Karen Wagner | General Partner | 4 | https://shizune.co/investors/profile/karen-wagner |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ona Therapeutics | Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $86.6M | Series B | Jun 04, 2026 |  |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M | Series C | Apr 14, 2026 |  |
| Ona Therapeutics | Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $11.6M | Venture - Series Unknown | Oct 09, 2025 |  |
| Splice Bio | Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $135M | Series B | Jun 11, 2025 |  |
| ReproNovo | ReproNovo is providing patients all over the world with significant improvement by developing cutting-edge therapeutic solutions for uterine disorders including adenomyosis and for male and female infertility. | $65M | Series A | May 21, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M |  | Apr 03, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M | Series F | Apr 03, 2025 |  |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $135M | Series B | Nov 25, 2024 |  |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $17.3M | Series A | May 29, 2024 |  |
| Memo Therapeutics | Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M | Series C | May 07, 2024 |  |

10 of 81 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 15 deals together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 15 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 13 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 12 deals together
- [Criteria Venture Tech](https://shizune.co/investors/profile/caixa-capital) — VC Fund, 11 deals together
- [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 9 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Europe](https://shizune.co/investors/biotechnology-investors-europe)
- [Biotechnology VC Funds in Europe](https://shizune.co/investors/biotechnology-vc-funds-europe)
- [Biotech Investors in Europe](https://shizune.co/investors/biotech-investors-europe)
- [Biotech VC Funds in Europe](https://shizune.co/investors/biotech-vc-funds-europe)
- [Health Care Investors in Spain](https://shizune.co/investors/health-care-investors-spain)
- [Health Care VC Funds in Spain](https://shizune.co/investors/health-care-vc-funds-spain)

## FAQ

### What does Ysios Capital invest in?

Ysios Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 81 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Ysios Capital's check size?

Ysios Capital typically joins rounds of $3.8M–$62M at Series A, $20M–$135M at Series B and $27M–$80M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ysios Capital participates in.

### How do I contact Ysios Capital?

Public channels for Ysios Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Ysios Capital?

The team at Ysios Capital includes Cristina Garmendia (Founding Partner and Member of the Board), Claudia D’Augusta (Venture Partner) and Guillem Laporta (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co